[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.202.12. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
September 17, 2008

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death

JAMA. 2008;300(11):1295-1299. doi:10.1001/jama.300.11.1296-a

To the Editor: From 1997 to early 1998, we were members of the data and safety monitoring board (DSMB) for Baxter Healthcare's US study of diaspirin cross-linked hemoglobin (DCLHb) in adult trauma patients experiencing hemorrhagic shock.1,2 Thus, we read with interest the study by Dr Natanson and colleagues3 describing the cumulative experience and adverse outcomes associated with the use of hemoglobin-based blood substitutes (HBBSs).3 While the cumulative adverse outcome data for HBBSs speak for themselves, the authors imply there has been a consistent pattern of delay in the release and publication of negative trial results with HBBSs.

First Page Preview View Large
First page PDF preview
First page PDF preview
×